Director dealings: Mercia Asset Management CFO raises stake.


Mercia Asset Management revealed on Thursday that chief financial officer Martin Glanfield had acquired 145,829 ordinary shares in the AIM-listed asset manager.

Source: Sharecast

Glanfield, who took over CFO in October 2014, purchased the shares on Wednesday at an average price of 28.80p each, for a total value of £41,998.75.

Following the transaction, Glanfield holds a beneficial interest in 1.74m ordinary Mercia shares, representing approximately 0.4% of the company's issued share capital.

As of 1615 GMT, Mercia shares were down 0.78% at 28.78p.

Reporting by Iain Gilbert at Sharecast.com

Top Director Buys

Mercia Asset Management (MERC)
Director name: Glanfield,Martin James
Amount purchased: 145,829 @ 28.80p
Value: �41,998.75

Trident Royalties (TRR)
Director name: Hughes,Richard John
Amount purchased: 115,000 @ 31.88p
Value: �36,662.00

Totally (TLY)
Director name: Stilwell ,Simon
Amount purchased: 550,000 @ 6.10p
Value: �33,550.00

Trident Royalties (TRR)
Director name: Hughes,Richard John
Amount purchased: 59,000 @ 32.80p
Value: �19,352.00

Totally (TLY)
Director name: Stilwell ,Simon
Amount purchased: 250,000 @ 6.17p
Value: �15,425.00

Elementis (ELM)
Director name: Woon,Clement
Amount purchased: 10,000 @ 121.00p
Value: �12,100.00

Totally (TLY)
Director name: Stilwell ,Simon
Amount purchased: 200,000 @ 6.00p
Value: �12,000.00

Trident Royalties (TRR)
Director name: Hughes,Richard John
Amount purchased: 26,000 @ 31.70p
Value: �8,242.00

Top Director Sells

London Stock Exchange Group (LSEG)
Director name: Brand,Martin
Amount sold: 37,329 @ 10,123.00p
Value: �3,778,814.80

London Stock Exchange Group (LSEG)
Director name: Brand,Martin
Amount sold: 27,945 @ 10,123.00p
Value: �2,828,872.44

Altitude Group (ALT)
Director name: Varley,Martin Roy
Amount sold: 578,334 @ 35.51p
Value: �205,354.84

Altitude Group (ALT)
Director name: Varley,Martin Roy
Amount sold: 50,000 @ 40.13p
Value: �20,062.50

Maxcyte (di) (MXCT)
Director name: Johnston ,John
Amount sold: 1,085 @ 461.50p
Value: �5,007.27

Maxcyte (di) (MXCT)
Director name: Johnston ,John
Amount sold: 735 @ 460.50p
Value: �3,384.68

Maxcyte (di) (MXCT)
Director name: Johnston ,John
Amount sold: 597 @ 455.00p
Value: �2,716.35

Maxcyte (di) (MXCT)
Director name: Johnston ,John
Amount sold: 452 @ 462.00p
Value: �2,088.24

Maxcyte (di) (MXCT)
Director name: Johnston ,John
Amount sold: 388 @ 456.00p
Value: �1,769.28

Maxcyte (di) (MXCT)
Director name: Johnston ,John
Amount sold: 372 @ 463.00p
Value: �1,722.36

Maxcyte (di) (MXCT)
Director name: Johnston ,John
Amount sold: 226 @ 462.50p
Value: �1,045.25

Maxcyte (di) (MXCT)
Director name: Johnston ,John
Amount sold: 226 @ 456.50p
Value: �1,031.69

Maxcyte (di) (MXCT)
Director name: Johnston ,John
Amount sold: 200 @ 453.00p
Value: �906.00

Maxcyte (di) (MXCT)
Director name: Johnston ,John
Amount sold: 134 @ 459.00p
Value: �615.06

Maxcyte (di) (MXCT)
Director name: Johnston ,John
Amount sold: 130 @ 454.00p
Value: �590.20

Maxcyte (di) (MXCT)
Director name: Johnston ,John
Amount sold: 127 @ 457.00p
Value: �580.39

Maxcyte (di) (MXCT)
Director name: Johnston ,John
Amount sold: 100 @ 459.50p
Value: �459.50

Maxcyte (di) (MXCT)
Director name: Johnston ,John
Amount sold: 100 @ 457.50p
Value: �457.50

Maxcyte (di) (MXCT)
Director name: Johnston ,John
Amount sold: 74 @ 460.00p
Value: �340.40

Maxcyte (di) (MXCT)
Director name: Johnston ,John
Amount sold: 28 @ 452.00p
Value: �126.56

Maxcyte (di) (MXCT)
Director name: Johnston ,John
Amount sold: 26 @ 455.50p
Value: �118.43

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.